回顾与思考——丙型肝炎防治研究三十年
丙型肝炎的防治研究约有三十余年,取得了辉煌成果：HCV的发现和证明创造了人类发现新生命的先河;重视HCV分子生物学、感染免疫及发病机制等基础研究,是传染病学研究的基本规律;聚乙二醇干扰素联合利巴韦林标准化抗病毒治疗获得成功,尤其对中国人持续病毒学应答率高达80%以上,是细胞因子成功临床应用的典范;直接抗病毒药物或联合应用使临床治愈所有丙型肝炎患者成为可能,这是一个最成功的借鉴;持续病毒感染并在一定条件下维持免疫稳态是机体与病毒相互作用的结果,丙型肝炎疫苗研究还将继续。...
Saved in:
| Published in | 临床肝胆病杂志 Vol. 31; no. 11; pp. 1803 - 1806 |
|---|---|
| Main Author | |
| Format | Journal Article |
| Language | Chinese |
| Published |
中国人民解放军第四军医大学唐都医院传染科,西安,710038
2015
|
| Subjects | |
| Online Access | Get full text |
| ISSN | 1001-5256 |
| DOI | 10.3969/j.issn.1001-5256.2015.11.009 |
Cover
| Abstract | 丙型肝炎的防治研究约有三十余年,取得了辉煌成果：HCV的发现和证明创造了人类发现新生命的先河;重视HCV分子生物学、感染免疫及发病机制等基础研究,是传染病学研究的基本规律;聚乙二醇干扰素联合利巴韦林标准化抗病毒治疗获得成功,尤其对中国人持续病毒学应答率高达80%以上,是细胞因子成功临床应用的典范;直接抗病毒药物或联合应用使临床治愈所有丙型肝炎患者成为可能,这是一个最成功的借鉴;持续病毒感染并在一定条件下维持免疫稳态是机体与病毒相互作用的结果,丙型肝炎疫苗研究还将继续。 |
|---|---|
| AbstractList | R512.63; 丙型肝炎的防治研究约有三十余年,取得了辉煌成果:HCV的发现和证明创造了人类发现新生命的先河;重视HCV分子生物学、感染免疫及发病机制等基础研究,是传染病学研究的基本规律;聚乙二醇干扰素联合利巴韦林标准化抗病毒治疗获得成功,尤其对中国人持续病毒学应答率高达80％以上,是细胞因子成功临床应用的典范;直接抗病毒药物或联合应用使临床治愈所有丙型肝炎患者成为可能,这是一个最成功的借鉴;持续病毒感染并在一定条件下维持免疫稳态是机体与病毒相互作用的结果,丙型肝炎疫苗研究还将继续. 丙型肝炎的防治研究约有三十余年,取得了辉煌成果：HCV的发现和证明创造了人类发现新生命的先河;重视HCV分子生物学、感染免疫及发病机制等基础研究,是传染病学研究的基本规律;聚乙二醇干扰素联合利巴韦林标准化抗病毒治疗获得成功,尤其对中国人持续病毒学应答率高达80%以上,是细胞因子成功临床应用的典范;直接抗病毒药物或联合应用使临床治愈所有丙型肝炎患者成为可能,这是一个最成功的借鉴;持续病毒感染并在一定条件下维持免疫稳态是机体与病毒相互作用的结果,丙型肝炎疫苗研究还将继续。 |
| Author | 贾战生 |
| AuthorAffiliation | 中国人民解放军第四军医大学唐都医院传染科,西安710038 |
| AuthorAffiliation_xml | – name: 中国人民解放军第四军医大学唐都医院传染科,西安,710038 |
| Author_FL | JIA Zhansheng |
| Author_FL_xml | – sequence: 1 fullname: JIA Zhansheng |
| Author_xml | – sequence: 1 fullname: 贾战生 |
| BookMark | eNo9j8tKAzEUhrOoYK19CXHhZsZkkpyZLKV4g4Kb7ksmM6lTaqodROyq1pUUu-pCkRZdui0iFcGHkU4vb2GkIpyfAz8f5_BtoJxpmhihbYJdKkDs1t0kTY1LMCYO9zi4HibcJcTFWORQ_r9fR8U0TULMCQXBOOQRZE-j5cvXdNKfdYaLzu13Z2BnOnnMRr1Fdzjv9pcP49n4c_48mL--Tyd32f1N9vG2ida0bKRx8W8XUOVgv1I6csonh8elvbKjAAvHj6M41BJrDjqQvuKKhx6jmHPmC8wCShgLNGORkoHQHo0BQssB5z4wRRktoJ3V2StptDS1ar152TL2YbWhalHYbv96EqsnLLq1QtVp09QuEguft5Iz2bquAkAAlNj8ABcqaZE |
| ClassificationCodes | R512.63 |
| ContentType | Journal Article |
| Copyright | Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| Copyright_xml | – notice: Copyright © Wanfang Data Co. Ltd. All Rights Reserved. |
| DBID | 2RA 92L CQIGP W91 ~WA 2B. 4A8 92I 93N PSX TCJ |
| DOI | 10.3969/j.issn.1001-5256.2015.11.009 |
| DatabaseName | 维普_期刊 中文科技期刊数据库-CALIS站点 中文科技期刊数据库-7.0平台 中文科技期刊数据库-医药卫生 中文科技期刊数据库- 镜像站点 Wanfang Data Journals - Hong Kong WANFANG Data Centre Wanfang Data Journals 万方数据期刊 - 香港版 China Online Journals (COJ) China Online Journals (COJ) |
| DatabaseTitleList | |
| DeliveryMethod | fulltext_linktorsrc |
| Discipline | Medicine |
| DocumentTitleAlternate | Retrospect and reflection： the past 30 years of research on hepatitis C prophylaxis and treatment |
| DocumentTitle_FL | Retrospect and reflection: the past 30 years of research on hepatitis C prophylaxis and treatment |
| EndPage | 1806 |
| ExternalDocumentID | lcgdbzz201511009 666863186 |
| GroupedDBID | -05 2B. 2C~ 2RA 5XA 5XF 92F 92I 92L ABDBF ACGFS ALMA_UNASSIGNED_HOLDINGS CCEZO CIEJG CQIGP CW9 EAD EAP EOJEC ESX GROUPED_DOAJ IPNFZ OBODZ OK1 RIG RNS TCJ TGQ U1G U5O W91 ~WA 4A8 93N ABJNI ACUHS PSX |
| ID | FETCH-LOGICAL-c609-7edebfa0f56f8a7c5c5b24305547904831448f44dca89f23e66b8a7655764c343 |
| ISSN | 1001-5256 |
| IngestDate | Thu May 29 03:59:49 EDT 2025 Wed Feb 14 10:23:03 EST 2024 |
| IsPeerReviewed | true |
| IsScholarly | true |
| Issue | 11 |
| Keywords | 肝炎,丙型 病毒性肝炎疫苗 抗病毒药 |
| Language | Chinese |
| LinkModel | OpenURL |
| MergedId | FETCHMERGED-LOGICAL-c609-7edebfa0f56f8a7c5c5b24305547904831448f44dca89f23e66b8a7655764c343 |
| Notes | hepatitis C ; antiviral agents ; viral hepatitis vaccines JIA Zhansheng. （ Centre of Diagnosis and Treatment for Infectious Diseases of Chinese PLA, Tangdu Hospital, Fourth Military Medical Univer- sity, Xi＇an 710038, China） The research on prophylaxis and treatment of hepatitis C has been performed for more than 30 years, with outstanding achieve- ments. The discovery and confirmation of hepatitis C virus （HCV） was a milestone for how humans discovered new life. Emphasis on HCV molecular biology, infection immunity, and pathogenesis is the basic rule for scientific research on infectious diseases. PEG - IFN combined with ribavirin as the standardized antiviral treatment has been a great success; this combination therapy achieves a sustained viral response more than 80% in Chinese people, which is a typical example for successful clinical application of cytokines. Direct - acting antiviral agent （DAA） or combined application has made it possible to cure all patients infected with hepatitis C, which is the most |
| PageCount | 4 |
| ParticipantIDs | wanfang_journals_lcgdbzz201511009 chongqing_primary_666863186 |
| PublicationCentury | 2000 |
| PublicationDate | 2015 |
| PublicationDateYYYYMMDD | 2015-01-01 |
| PublicationDate_xml | – year: 2015 text: 2015 |
| PublicationDecade | 2010 |
| PublicationTitle | 临床肝胆病杂志 |
| PublicationTitleAlternate | Chinese Journal of Clinical Hepatology |
| PublicationTitle_FL | Journal of Clinical Hepatology |
| PublicationYear | 2015 |
| Publisher | 中国人民解放军第四军医大学唐都医院传染科,西安,710038 |
| Publisher_xml | – name: 中国人民解放军第四军医大学唐都医院传染科,西安,710038 |
| SSID | ssib051369456 ssj0041983 ssib001103858 ssib053243598 ssib002264326 ssib038074677 |
| Score | 1.979873 |
| Snippet | ... R512.63;... |
| SourceID | wanfang chongqing |
| SourceType | Aggregation Database Publisher |
| StartPage | 1803 |
| SubjectTerms | 抗病毒药 病毒性肝炎疫苗 肝炎,丙型 |
| Title | 回顾与思考——丙型肝炎防治研究三十年 |
| URI | http://lib.cqvip.com/qk/90100X/201511/666863186.html https://d.wanfangdata.com.cn/periodical/lcgdbzz201511009 |
| Volume | 31 |
| hasFullText | 1 |
| inHoldings | 1 |
| isFullTextHit | |
| isPrint | |
| link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnR1NaxNBdIgpFC_iJ9aqVOgcN-7HfB4zJqEI9RSht7CzH-1BUj_SS06xnkTtqQdFWvTotYhEBH-MJE37L3xvd5OsUIoKYXiZefPe7L7ZeW9233tDyGrkBal1rXRCGUoHJkXghFbHTuy7-JGIhWl2Dtn6I7H2mD3c4BuVytuS19JOz9ai_plxJf8jVagDuWKU7D9IdkYUKgAG-UIJEobyr2RMm5xqQ3WTNjWte9QAwKhRVAEgMieGBm0qBFQwdWtgJSBD1jqj06TKZMh-1ksioDLKWlHjI0EojcGmet4dAE2NmDLN6KgGGKcIGGhiZdu3QDMsa61TVS-xUzhCJZCmBtYc2UE9tCJyi-qZvkRcoGHyS1Q4OuzEqG6VX2Hk4ZvFeoseXdzPc4tPF-RCLRQTzystr55yg5Kqhr_iLDUQaKEzNYA8ajMe6MjHa5iz1dVz9TdzSoSNnBKwxIkLZMGX0uNVslA3DdOam5ee-0fuHwxCLpm_mLufldIDci8Qms1zFXEwXjFh4tRSYJ5WeQBIMcBFslqM_v55Y8c0IFvb3c1nYNxksWbdNOxulsyi9mVyqdjPrNTzyXmFVPpbV8nieuGxcY2I8cfD088_R8O948HByeDVr8E-_EbDD-PDNye7B5PdvdP3R8dHPyaf9idfvo2Gr8fvXo6_f71O2q1m-8GaU5zV4UTC1Y5M4sSmoZtykapQRjzi1s-yyTGp8dQC2LerlLE4CpVO_SARwgKe4LDdZVHAghuk2t3uJjfJSuxyFbHUt_gF2goRRpFOlI5DKa2UiV0iy7Or7zzNU7J0ZrJbIveK-9EpHtQXnSfRZmz7fbyDmCBR3zqXwjK5iJj5a7bbpNp7vpPcAcOzZ-8W8-E3hAlkng |
| linkProvider | EBSCOhost |
| openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=%E5%9B%9E%E9%A1%BE%E4%B8%8E%E6%80%9D%E8%80%83%E2%80%94%E2%80%94%E4%B8%99%E5%9E%8B%E8%82%9D%E7%82%8E%E9%98%B2%E6%B2%BB%E7%A0%94%E7%A9%B6%E4%B8%89%E5%8D%81%E5%B9%B4&rft.jtitle=%E4%B8%B4%E5%BA%8A%E8%82%9D%E8%83%86%E7%97%85%E6%9D%82%E5%BF%97&rft.au=%E8%B4%BE%E6%88%98%E7%94%9F&rft.date=2015&rft.issn=1001-5256&rft.volume=31&rft.issue=11&rft.spage=1803&rft.epage=1806&rft_id=info:doi/10.3969%2Fj.issn.1001-5256.2015.11.009&rft.externalDocID=666863186 |
| thumbnail_s | http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fimage.cqvip.com%2Fvip1000%2Fqk%2F90100X%2F90100X.jpg http://utb.summon.serialssolutions.com/2.0.0/image/custom?url=http%3A%2F%2Fwww.wanfangdata.com.cn%2Fimages%2FPeriodicalImages%2Flcgdbzz%2Flcgdbzz.jpg |